|
Goodwill and Other Intangibles - Textual (Detail) (USD $)
|
12 Months Ended | 12 Months Ended | 3 Months Ended | 1 Months Ended | 12 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2013
Zetia [Member]
|
Dec. 31, 2013
Vytorin [Member]
|
Dec. 31, 2013
Nasonex [Member]
|
Dec. 31, 2013
Claritin Rx [Member]
|
Dec. 31, 2013
NuvaRing [Member]
|
Dec. 31, 2013
Products Marketed for Treatment of Chronic Hepatitis C Virus [Member]
|
Dec. 31, 2013
Saphris/Sycrest [Member]
|
Dec. 31, 2013
Rebetol [Member]
|
Dec. 31, 2013
Preladenant [Member]
|
Dec. 31, 2013
Supera [Member]
|
Jul. 31, 2013
Physicians Interactive [Member]
|
Nov. 30, 2013
Health Management Resources Corporation [Member]
|
Dec. 31, 2013
Health Management Resources Corporation [Member]
Physicians Interactive [Member]
|
|
| Intangible Assets Excluding Goodwill [Line Items] | ||||||||||||||||
| Noncontrolling interest, ownership percentage | 49.00% | 24.00% | ||||||||||||||
| Business combination, consideration transferred | $ 97,000,000 | $ 87,000,000 | ||||||||||||||
| Acquisitions | 291,000,000 | 175,000,000 | ||||||||||||||
| Other Intangibles, Net | 23,801,000,000 | 29,083,000,000 | 4,700,000,000 | 2,600,000,000 | 1,300,000,000 | 1,500,000,000 | 867,000,000 | 1,300,000,000 | ||||||||
| Intangible asset impairment charge related to marketed product | 486,000,000 | 118,000,000 | 330,000,000 | 156,000,000 | ||||||||||||
| IPR&D reclassified to products and product rights upon receipt of marketing approval | 346,000,000 | 78,000,000 | 666,000,000 | |||||||||||||
| In-process research and development impairment charges | 279,000,000 | 200,000,000 | 587,000,000 | 181,000,000 | 15,000,000 | |||||||||||
| Amortization expense for intangible assets | 4,800,000,000 | 5,000,000,000 | 5,100,000,000 | |||||||||||||
| Estimated Future Amortization Expense, 2014 | 4,300,000,000 | |||||||||||||||
| Estimated Future Amortization Expense, 2015 | 4,100,000,000 | |||||||||||||||
| Estimated Future Amortization Expense, 2016 | 3,400,000,000 | |||||||||||||||
| Estimated Future Amortization Expense, 2017 | 3,100,000,000 | |||||||||||||||
| Estimated Future Amortization Expense, 2018 | $ 1,600,000,000 | |||||||||||||||